import type { ServiceLandingExpandedContent } from '@/data/serviceLandingContent';

const DELIVERABLES = [
  'Executive summary mapped to one commercial, access, or medical decision',
  'Stakeholder segmentation with influence and objection themes',
  'Quantitative sizing or adoption metrics where the objective requires measurement',
  'Qualitative depth modules for behaviour and pathway questions',
  '30/60/90 action plan with owners and evidence gaps flagged',
  'Audit-ready methodology appendix for internal review or regulator dialogue',
];

const SPECIALTY_EXPANDED: Record<
  'japan-medical-disposables-market' | 'italy-portable-diagnostic-devices-market' | 'gcc-medication-management-market',
  ServiceLandingExpandedContent
> = {
  'japan-medical-disposables-market': {
    hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
    regulatory: {
      heading: 'PMDA, NHI, and hospital standards shaping Japan disposables',
      paragraphs: [
        'Japan’s medical disposables market sits under PMDA device classification for many high-risk categories, but a large share of hospital consumables is governed through internal quality standards, infection-control policies, and group purchasing contracts rather than a single national “disposables formulary.” BioNixus maps which SKUs face formal device filing versus which are selected purely on nursing workflow, sterility assurance, and total delivered cost.',
        'The Ministry of Health, Labour and Welfare (MHLW) infection-prevention guidance and hospital accreditation expectations (including JCI-aligned programmes at major university centres) set baseline requirements for drapes, antiseptics, PPE, and procedure packs. Research therefore interviews infection-control committees and nursing quality leads—not only procurement—to explain why premium products retain share after tender compression.',
        'NHI reimbursement mechanics influence disposables indirectly: products tied to reimbursed procedures or bundled DRG payments face different switching economics than purely operational consumables. Fieldwork separates “reimbursement-linked” disposables from “operating-cost” disposables so manufacturers do not misread volume drivers.',
        'Domestic Japanese manufacturers remain reference suppliers for many categories; imported disposables must clear additional diligence on Japanese labelling, sterility documentation, and after-sales service. BioNixus tests whether “made in Japan” positioning still wins against lower unit-cost imports when nursing usability scores are equal.',
        'Post-market vigilance and recall history shape hospital dual-source policies. Shortages of gloves, syringes, or antiseptics during global supply shocks left lasting preference for vendors with demonstrable continuity plans—research captures how procurement weights resilience versus price after 2020–2022 experience.',
        'Teaching hospitals run resident training programmes that lock in specific pack configurations; changing a tray layout requires retraining across rotations. BioNixus documents training-linked switching costs when vendors propose kit redesigns tied to standardization votes.',
        'Dialysis, endoscopy, and ICU sub-specialties maintain separate disposable budgets from general ward materials management—studies scope by care setting so forecasts do not assume one hospital-wide tender covers all high-turn SKUs.',
      ],
    },
    marketContext: {
      heading: 'How Japan hospitals buy and standardize disposables',
      paragraphs: [
        'Japan’s ageing inpatient base keeps baseline consumable intensity high even as length-of-stay shortens. Ward turnover pressure means nursing managers veto products that add steps to medication or line care—even when procurement negotiates a lower unit price.',
        'Group purchasing organizations and hospital chains standardize SKUs across member facilities. A win at the GPO level can flip volume overnight; conversely, a single influential university hospital pilot can block national standardization if infection-control publishes a negative evaluation.',
        'Private acute hospitals and medical corporations compete on patient experience and infection metrics; disposables choices signal quality to insurers and referral physicians. Public hospitals face tighter budget caps but still fund infection-control upgrades when quality indicators are at risk.',
        'Sustainability criteria—reduced packaging, recyclable materials, reprocessing where permitted—appear increasingly in evaluation scorecards, especially at internationally affiliated hospitals. Claims require evidence; “green” labels without workflow proof rarely survive committee review.',
        'Export-oriented Japanese manufacturers sometimes use domestic hospital preference data to support GCC or ASEAN tenders. BioNixus can run linked modules: Japan adoption drivers plus Gulf procurement expectations when a single vendor strategy spans both regions.',
        'Competitive switching barriers include nurse training videos, kit redesign tied to specific procedure trays, and consignment inventory models. Research quantifies switching costs in nursing hours—not only price deltas—so commercial teams price retention investments correctly.',
        'Seasonal influenza and respiratory surges temporarily shift PPE and antiseptic mix; manufacturers planning FY forecasts need ward-level seasonality modules rather than annual average consumption models copied from Western Europe.',
        'Materials-management ERP integrations determine whether SKU changes propagate to all wards simultaneously or stall at sub-store level—BioNixus maps IT and logistics stakeholders when “standardization” projects under-deliver volume.',
      ],
    },
    services: {
      heading: 'Japan medical disposables research modules BioNixus delivers',
      items: [
        {
          title: 'Infection-control and nursing preference studies',
          description:
            'Structured interviews and ward observations on drapes, antiseptics, PPE, and packs—capturing workflow friction, sterility confidence, and brand loyalty independent of tender list price.',
        },
        {
          title: 'GPO and hospital tender intelligence',
          description:
            'Procurement stakeholder mapping, dual-source rules, and award criteria for high-turn categories; includes scenario testing on service-level guarantees and continuity plans.',
        },
        {
          title: 'SKU standardization and substitution research',
          description:
            'Pharmacy and materials-management modules on substitution behaviour when contracts change—critical for biosimilar-style competition in commoditized disposables.',
        },
        {
          title: 'Private vs public account segmentation',
          description:
            'Separate samples for medical corporations, university hospitals, and public prefectural networks so volume forecasts reflect where margin and decision speed differ.',
        },
        {
          title: 'Sustainability and green procurement tests',
          description:
            'Message and attribute testing for reduced-waste products with pre-specified evaluation against infection-control non-negotiables.',
        },
        {
          title: 'Linked Japan–GCC commercial modules',
          description:
            'Optional add-on interviews with Gulf procurement when Japanese manufacturing credentials support export tenders—aligned variable dictionaries for regional leadership readouts.',
        },
      ],
    },
    methodology: {
      heading: 'Methodology for Japan disposables fieldwork',
      paragraphs: [
        'Studies open with a decision memo: standardization win, tender defence, nursing-led premium retention, or export-linked positioning. Sampling follows that memo—mixing infection-control, nursing management, and procurement rather than averaging “hospital buyer” into one role.',
        'Qualitative depth (ward visits where permitted, remote card-sort exercises on pack design) precedes quantitative waves when the client needs hypothesis generation before sizing.',
        'Quant instruments use Japanese field with English sponsor readouts; medical terminology is reviewed with a Japanese-speaking clinical advisor before launch.',
        'Exclusion logs and role validation document who truly influences SKU permanency versus who only executes contract awards.',
        'Deliverables include an objection library ranked by committee stage—pilot, GPO review, annual re-tender—so medical affairs and sales align interventions.',
      ],
    },
    useCases: {
      heading: 'Categories where Japan disposables research concentrates',
      paragraph:
        'High-turn, committee-governed categories drive most primary research spend—not niche implants.',
      areas: [
        'Surgical drapes and procedure packs',
        'Antiseptics and skin prep',
        'PPE and isolation consumables',
        'Infusion and line-care sets',
        'Wound care and advanced dressings',
        'Dialysis and critical-care consumables',
      ],
    },
    process: {
      heading: 'Typical Japan disposables engagement timeline',
      steps: [
        {
          title: 'Week 1: scope and feasibility',
          body: 'Lock decision objective, category scope, and hospital types; confirm Japanese IRB or hospital permission needs for any on-site modules.',
        },
        {
          title: 'Weeks 2–3: qualitative or pilot wave',
          body: 'Infection-control and nursing depth interviews; optional procurement shadow interviews when tender calendars are known.',
        },
        {
          title: 'Weeks 4–6: quantitative field',
          body: 'National or regional survey with daily QC; segment cuts by hospital type and GPO membership where sample allows.',
        },
        {
          title: 'Week 7: readout and action plan',
          body: 'Executive summary, objection themes, and 30/60/90 actions tied to tender or standardization milestones.',
        },
      ],
    },
    deliverables: { heading: 'Deliverables', bullets: DELIVERABLES },
    decisionBlueprint: {
      why: 'Japan disposables revenue is won or lost on nursing usability and infection metrics—not list price alone.',
      evidence:
        'BioNixus modules consistently show that workflow friction scores predict SKU delisting one to two tender cycles before price becomes the stated reason.',
      next: 'Share target categories, hospital segments, and the commercial decision (win, retain, or export-link). BioNixus returns a scoped proposal within 48 hours.',
    },
    faqs: [
      {
        question: 'What is included in Japan medical disposables market research?',
        answer:
          'Primary research on hospital consumables— infection-control products, procedure packs, PPE, infusion sets, and related high-turn categories—through nursing, infection-control, materials-management, and procurement stakeholders. Outputs explain standardization, tender awards, and premium retention drivers rather than syndicated market size tables.',
      },
      {
        question: 'How long does a Japan disposables study take?',
        answer:
          'Qualitative-only modules often complete in three to four weeks; mixed qual-quant programmes typically six to seven weeks from scope to executive readout, depending on hospital permission requirements and sample rarity.',
      },
      {
        question: 'Does BioNixus cover both public and private Japanese hospitals?',
        answer:
          'Yes. Samples are stratified by university, public prefectural, medical corporation, and private acute settings so results reflect real volume concentration—not Tokyo-only panels.',
      },
      {
        question: 'Can research link Japan domestic preference to GCC export tenders?',
        answer:
          'Optional linked modules interview Gulf procurement on how Japanese manufacturing credentials and continuity plans influence tender scoring—using harmonized topic guides for regional roll-ups.',
      },
      {
        question: 'How do nursing unions and ward culture affect Japan disposables switching?',
        answer:
          'Even when procurement awards a lower-cost contract, ward councils and head nurses can delay rollout if usability trials fail or if infection-control publishes a caution memo. BioNixus captures cultural veto points—training burden, tray familiarity, and night-shift workflow—so manufacturers budget change-management alongside price concessions. Ignoring nursing culture produces “paper wins” where the contract changes but bedside SKU usage does not.',
      },
      {
        question: 'What sample sizes are realistic for Japan GPO stakeholder research?',
        answer:
          'Qualitative GPO and procurement modules typically include eight to fifteen structured interviews per target GPO or chain, supplemented by nursing depth interviews in two to four member hospitals. Quantitative waves scale to sixty to one hundred twenty completes per segment when sponsors need measurable preference shares—feasibility is confirmed in writing before field opens.',
      },
    ],
  },
  'italy-portable-diagnostic-devices-market': {
    hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
    regulatory: {
      heading: 'IVDR, regional procurement, and POCT governance in Italy',
      paragraphs: [
        'Portable diagnostic devices in Italy fall under EU IVDR expectations with Notified Body involvement for many classes; hospital POCT programmes add another layer—local method validation, quality control schedules, and LIS integration before clinicians may order near-patient tests at scale.',
        'AIFA influences which diagnostics tie to reimbursed pathways, but much POCT adoption is hospital-budgeted operating expenditure. Research must separate “reimbursement-enabled” panels from “ED turnaround” investments that never appear on a national drug or test tariff.',
        'Regional health systems (ASL) and large hospital groups publish tenders with interoperability clauses—HIS, LIS, cybersecurity, and data residency. Vendors that win pilots but fail IT diligence rarely scale; BioNixus interviews CIO and clinical engineering early in studies scoped for connectivity-heavy platforms.',
        'Professional society and regional POCT network guidance shapes which analytes hospitals decentralize versus keep on core lab tracks. Fieldwork references current Italian laboratory medicine society positions without substituting promotional claims for independent stakeholder views.',
        'Post-market performance and EQA participation are tender table stakes. Research documents how laboratory directors weight external quality assessment history versus marketing collateral when renewing reagent rental contracts.',
        'University hospitals participate in multi-centre research networks that influence which POCT analytes are considered “research-grade” versus routine care—vendor claims must align with how directors classify tests for billing and governance.',
        'Blood gas and critical-care handhelds face separate biomedical engineering fleets from core laboratory POCT; studies include biomed when sponsors sell devices that touch both ED and ICU workflows.',
      ],
    },
    marketContext: {
      heading: 'Italian POCT and portable diagnostics adoption dynamics',
      paragraphs: [
        'Emergency departments and high-acuity wards drive first-wave POCT adoption—troponin, lactate, blood gas, and selected infection markers—where minutes affect admission decisions. Community and ambulatory expansion follows only after core lab directors trust connectivity and QC automation.',
        'Regional consolidation of laboratory services creates push-pull: central labs argue for retained volume; clinical departments argue for ward-side turnaround. BioNixus maps who wins by indication, not by national average.',
        'Reagent rental and per-test economics dominate renewals. Handheld platforms with attractive capital price but opaque per-test cost lose renewals when throughput rises—research models total cost with Italian hospital finance stakeholders.',
        'Chronic cardiometabolic and respiratory monitoring expands portable diagnostics beyond acute care, but reimbursement and GP network integration lag hospital POCT maturity. Studies scope ambulatory separately to avoid false-negative demand signals.',
        'Italian manufacturers and global IVD majors compete on service density—field engineers, loaner devices during maintenance, Italian-language helpdesk. Service attributes often decide renewals after technical parity is achieved.',
        'Cyber incidents and GDPR enforcement increased IT security review time for connected devices. Research captures minimum security documentation packs that unblock tenders—reducing surprise six-month delays.',
        'Primary-care networks in Northern and Central Italy adopt POCT slower than Lombardy and Emilia-Romagna hospital hubs—national launches should sequence regions by laboratory governance maturity, not population alone.',
        'Companion diagnostics and therapy-linked POCT create joint medical-laboratory committees; device vendors selling hardware without therapy stakeholders misread decision cycles for oncology or cardiometabolic panels.',
      ],
    },
    services: {
      heading: 'Italy portable diagnostics research modules',
      items: [
        {
          title: 'POCT programme and governance mapping',
          description:
            'Interviews with laboratory directors on method validation, QC cadence, and decentralization policies by analyte and care setting.',
        },
        {
          title: 'Clinical pathway and ordering research',
          description:
            'ED, ward, and ambulatory lead interviews on when near-patient tests change admission, treatment, or discharge—quantified where sponsors require adoption metrics.',
        },
        {
          title: 'Regional tender and procurement intelligence',
          description:
            'ASL and hospital-group RFP criteria, scoring weights for interoperability, service, and reagent economics.',
        },
        {
          title: 'Connectivity and LIS integration diligence',
          description:
            'CIO, biomed, and laboratory IT modules on interface requirements, middleware, and cybersecurity gates.',
        },
        {
          title: 'Competitive installed-base and switching research',
          description:
            'Switch-cost assessment versus central lab automation and competing handheld platforms—including reagent contract lock-in.',
        },
        {
          title: 'IVDR evidence and PMS expectation research',
          description:
            'How laboratory and quality teams expect post-market surveillance and performance data to be presented during renewals.',
        },
      ],
    },
    methodology: {
      heading: 'Methodology for Italy portable diagnostics studies',
      paragraphs: [
        'Indication-first sampling: ED-focused POCT studies overweight trauma and chest-pain centres; ambulatory modules overweight diabetes and respiratory networks.',
        'Italian field with English executive readouts; instruments reviewed with a laboratory medicine advisor before launch.',
        'Qualitative pathway mapping precedes quant when clients enter new analytes or regions without prior Italian POCT share.',
        'Segmentation by region and hospital group type avoids Lombardy-only bias when national roll-ups are required.',
        'Deliverables tie findings to tender calendars and renewal windows so commercial teams act before RFP publication—not after award.',
        'Shadowing laboratory quality meetings (remote or in-person where permitted) reveals unstated veto criteria that do not appear in RFP text—especially for connectivity and cybersecurity.',
        'When sponsors sell both instruments and reagents, conjoint-style trade-off modules separate capital from consumable willingness-to-pay so pricing teams do not optimize the wrong lever.',
        'Investigator-sponsored POCT research sometimes precedes commercial scale-up; BioNixus flags when academic pilots create false demand signals that do not translate to paid hospital budgets.',
      ],
    },
    useCases: {
      heading: 'Portable diagnostics use cases BioNixus researches in Italy',
      paragraph: 'Near-patient testing decisions are indication-specific; programmes scope accordingly.',
      areas: [
        'Emergency troponin and cardiac panels',
        'Blood gas and critical-care handhelds',
        'Infection and respiratory POCT',
        'Diabetes and cardiometabolic point-of-care',
        'Coagulation near-patient testing',
        'Connected home-to-hospital monitoring pilots',
      ],
    },
    process: {
      heading: 'Typical Italy portable diagnostics timeline',
      steps: [
        { title: 'Week 1: scope', body: 'Define analyte, care setting, and decision (pilot scale, tender win, renewal defence).' },
        { title: 'Weeks 2–4: field', body: 'Laboratory, clinical, and IT interviews with optional quant follow-up.' },
        { title: 'Week 5: synthesis', body: 'Objection library, tender implications, and connectivity checklist.' },
        { title: 'Week 6: readout', body: 'Executive workshop with medical, commercial, and access stakeholders.' },
      ],
    },
    deliverables: { heading: 'Deliverables', bullets: DELIVERABLES },
    decisionBlueprint: {
      why: 'Italian POCT scale-ups fail on LIS integration and laboratory governance—not device specifications alone.',
      evidence:
        'BioNixus tender modules show connectivity and QC automation scores predict POCT expansion beyond pilot wards with higher accuracy than clinician enthusiasm scores alone.',
      next: 'Send target analytes, regions, and platform class; receive a feasibility-backed proposal within 48 hours.',
    },
    faqs: [
      {
        question: 'What is the Italy portable diagnostic devices market?',
        answer:
          'Near-patient and handheld diagnostic platforms used in hospitals, selected ambulatory networks, and community pathways—researched via laboratory directors, clinicians, IT, and procurement rather than consumer retail panels.',
      },
      {
        question: 'How does IVDR affect Italy POCT research?',
        answer:
          'Studies document how Notified Body classification, performance evaluation expectations, and post-market surveillance requirements interact with hospital method-validation rules—so go-to-market plans reflect real activation time, not EU-average assumptions.',
      },
      {
        question: 'Can BioNixus research regional tender differences across Italy?',
        answer:
          'Yes. ASL and hospital-group tenders are mapped with scoring criteria and renewal cycles; samples stratify by region when national representativeness is required.',
      },
      {
        question: 'Does BioNixus connect portable diagnostics research to pharma or medtech portfolios?',
        answer:
          'Combined modules link POCT adoption to therapy initiation or monitoring protocols when sponsors need pathway evidence for access or medical affairs—not device revenue alone.',
      },
      {
        question: 'How long do Italy POCT method-validation projects delay scale-up?',
        answer:
          'Validation and LIS interface projects commonly add eight to sixteen weeks after device delivery before ward-wide ordering is authorized. BioNixus interviews laboratory quality teams to estimate realistic activation timelines by analyte complexity—lipid panels differ from coagulation or blood gas. Commercial plans that assume four-week go-live after tender award routinely miss revenue curves unless validation scope is pre-mapped.',
      },
      {
        question: 'Can BioNixus benchmark Italy POCT against Germany or France?',
        answer:
          'Harmonized topic guides allow EU peer comparisons on connectivity requirements, reagent economics, and laboratory governance—while keeping Italian ASL tender mechanics in country appendices. Roll-ups help regional leadership without forcing identical institutional assumptions that would distort local access realism.',
      },
    ],
  },
  'gcc-medication-management-market': {
    hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
    regulatory: {
      heading: 'National e-health, pharmacy law, and Gulf medication safety frameworks',
      paragraphs: [
        'Medication management in the GCC spans SFDA and MOH pharmacy regulations, hospital accreditation standards, and national e-health programmes that increasingly require e-prescribing and medicines reconciliation. BioNixus maps which requirements are mandatory versus aspirational in each country cell before fieldwork.',
        'Saudi Arabia’s Wasfaty platform links ambulatory prescribing to dispensary fulfilment; hospital closed-loop projects often must interoperate with broader MOH digital health roadmaps. UAE emirate health authorities (DHA, DOH) maintain distinct formulary and e-Rx integrations—research stratifies Dubai and Abu Dhabi when systems diverge.',
        'Medication-error reduction initiatives and patient-safety accreditation drive capital pharmacy automation in new mega-hospitals; older facilities may fund adherence software before robotics. Scoping separates capital from SaaS buying centres.',
        'Controlled medicines, cold-chain biologics, and high-cost specialty inventory visibility appear in tender specs alongside ADC deployments. Studies include chief pharmacists and quality leads when safety claims are central to the vendor story.',
        'Data residency and cloud hosting rules for patient medication data influence IT approval timelines—especially for multinational SaaS vendors. CIO interviews document minimum hosting and cybersecurity packs that prevent six-month stalls.',
        'Medication safety dashboards tied to accreditation visits create executive visibility for ADC error rates—vendors must translate technical features into metrics chief medical officers already track for Joint Commission-style reviews in private hospitals.',
        'Employer-funded digital adherence programmes in UAE and Saudi wellness initiatives sometimes bypass hospital pharmacy entirely; research scopes payer and HR stakeholders when the commercial model is B2B2C rather than inpatient capital.',
      ],
    },
    marketContext: {
      heading: 'GCC pharmacy automation, e-Rx, and adherence economics',
      paragraphs: [
        'New hospital openings in Saudi Arabia and the UAE create greenfield opportunities for automated dispensing, compounding workflows, and integrated e-prescribing—legacy retrofit markets behave differently; BioNixus segments by facility age and sponsor type.',
        'Pharmacy workforce shortages make automation attractive on paper, but nursing and pharmacy unions culturally resist changes that feel like deskilling. Research captures change-management barriers alongside ROI models.',
        'Payers and employers fund adherence programmes for diabetes, obesity, and cardiometabolic disease when total cost of care arguments are localized—generic global apps fail without Arabic content and insurer integration proof.',
        'NUPCO and private hospital group tenders bundle medication management with broader supply-chain awards; vendors must understand scoring when automation is secondary to injectable volume guarantees.',
        'Kuwait, Qatar, Oman, and Bahrain run smaller networks that can standardize quickly when leadership sponsors change—studies include these cells for regional roll-ups, not only KSA and UAE.',
        'Specialty drug growth increases need for inventory visibility and ADC accuracy; errors in high-cost bins trigger immediate executive scrutiny—research tests which safety narratives survive chief pharmacist challenge.',
        'Telepharmacy and hub-and-spoke models in UAE private groups change where medication checks occur—closed-loop projects must map remote verification workflows, not only ward bedside scanning.',
        'Insurance prior-authorization for high-cost outpatient drugs pushes adherence vendors to prove integration with payer portals; hospital-only automation research misses ambulatory revenue when sponsors sell across both channels.',
      ],
    },
    services: {
      heading: 'GCC medication management research modules',
      items: [
        {
          title: 'Hospital pharmacy automation adoption',
          description:
            'Chief pharmacist and nursing modules on ADC, unit-dose, and compounding automation—implementation friction, training, and ROI validation.',
        },
        {
          title: 'E-prescribing and closed-loop medication systems',
          description:
            'CIO and pharmacy informatics interviews on HIS integration, alert fatigue, and clinician workflow acceptance.',
        },
        {
          title: 'Wasfaty and ambulatory fulfilment linkage',
          description:
            'Saudi-specific modules on ambulatory prescribing, dispensary behaviour, and adherence touchpoints tied to national platforms.',
        },
        {
          title: 'Adherence and patient-support programme research',
          description:
            'Payer, employer, and hospital ambulatory stakeholders on funding criteria and outcome metrics for digital adherence tools.',
        },
        {
          title: 'Tender and procurement mapping',
          description:
            'NUPCO, hospital group, and private chain award criteria for capital versus SaaS medication management purchases.',
        },
        {
          title: 'Safety and error-reduction evidence tests',
          description:
            'Quality and patient-safety sponsor modules validating medication-error reduction claims before committee investment.',
        },
      ],
    },
    methodology: {
      heading: 'Methodology for GCC medication management studies',
      paragraphs: [
        'Country-cell design is default: Saudi, UAE (Dubai/Abu Dhabi when needed), Kuwait, Qatar, Oman, Bahrain—harmonized metrics with local appendices.',
        'Bilingual Arabic–English instruments for clinician and pharmacist modules; IT interviews often English with Arabic summary appendices for local affiliates.',
        'Decision-stage sampling separates greenfield automation, retrofit replacement, and adherence-only purchases to avoid averaged buyer profiles.',
        'Daily QC on quantitative waves; chief pharmacist role validation against institutional directories where permitted.',
        'Readouts connect to 30/60/90 milestones aligned to tender, go-live, or budget cycles—not generic quarterly slides.',
        'Pharmacy informatics stakeholders validate whether alert-fatigue narratives are genuine barriers or procurement negotiating tactics—pre-coded scales keep qualitative readouts auditable.',
        'Cross-country roll-ups preserve Saudi Wasfaty and UAE emirate splits in appendices so regional VPs can act without re-fielding identical interviews in each affiliate.',
        'Medication safety dashboards shown to hospital boards must use metrics committees already track—BioNixus aligns KPI dictionaries with accreditation scorecards before quant field opens.',
      ],
    },
    useCases: {
      heading: 'Therapy and care settings driving GCC medication management demand',
      paragraph: 'Automation and adherence priorities differ by care setting and drug economics.',
      areas: [
        'Acute inpatient ADC and closed-loop',
        'Oncology and specialty pharmacy inventory',
        'Ambulatory e-Rx and Wasfaty-linked fulfilment',
        'Diabetes and obesity adherence programmes',
        'Critical care and ICU medication workflows',
        'Employer and payer digital therapeutics adjacency',
      ],
    },
    process: {
      heading: 'Typical GCC medication management engagement timeline',
      steps: [
        { title: 'Week 1: scope', body: 'Define country cells, buyer type (capital vs SaaS), and decision milestone.' },
        { title: 'Weeks 2–5: field', body: 'Pharmacy, IT, quality, and payer modules with optional quant waves.' },
        { title: 'Week 6: synthesis', body: 'Tender implications, integration checklist, and objection library.' },
        { title: 'Week 7: readout', body: 'Regional roll-up with country appendices for affiliate action.' },
      ],
    },
    deliverables: { heading: 'Deliverables', bullets: DELIVERABLES },
    decisionBlueprint: {
      why: 'GCC medication management purchases are coalition decisions across pharmacy, IT, and patient safety—not pharmacy-only.',
      evidence:
        'BioNixus studies show IT integration and training burden predict go-live success more reliably than capital price alone across Saudi and UAE hospital networks.',
      next: 'Outline target countries, product class (automation, e-Rx, adherence), and milestone; receive a scoped GCC proposal within 48 hours.',
    },
    faqs: [
      {
        question: 'What is included in the GCC medication management market?',
        answer:
          'Hospital pharmacy automation, e-prescribing and closed-loop systems, inventory visibility for specialty drugs, and adherence / patient-support programmes—researched through chief pharmacists, CIOs, quality leaders, and payers across Gulf countries.',
      },
      {
        question: 'How does BioNixus handle Saudi Wasfaty in research design?',
        answer:
          'Saudi modules explicitly map ambulatory prescribing and fulfilment behaviour linked to Wasfaty where relevant—separate from inpatient closed-loop studies so ambulatory pull is not confused with ward automation demand.',
      },
      {
        question: 'Can one study cover all six GCC countries?',
        answer:
          'Yes, with harmonized core metrics and country appendices; sample plans reflect realistic chief pharmacist and IT depth in Oman, Bahrain, and Qatar versus KSA/UAE volume concentration.',
      },
      {
        question: 'Does medication management research connect to NUPCO tender strategy?',
        answer:
          'Optional tender modules document award criteria and bundling when automation sits inside broader supply awards—so vendors do not optimize hospital demos while losing on tender scoring.',
      },
      {
        question: 'What is the difference between GCC pharmacy automation and adherence software buyers?',
        answer:
          'Automation purchases route through capital committees, chief pharmacists, and biomed with multi-year depreciation logic; adherence SaaS often routes through payer innovation teams, employer wellness budgets, or ambulatory pharmacy directors with annual OPEX cycles. BioNixus separates samples so pipeline forecasts do not treat one chief pharmacist interview as proof of adherence demand—or vice versa.',
      },
      {
        question: 'How does BioNixus research closed-loop medication systems without promotional bias?',
        answer:
          'Clinician modules use neutral case vignettes and pre-coded reaction scales; sponsors receive thematic barriers and integration requirements rather than promotional claim testing. Compliance-friendly design keeps outputs usable for medical affairs and IT security review while still informing commercial prioritization.',
      },
    ],
  },
};

export type SpecialtyMarketDemandExpandedKey = keyof typeof SPECIALTY_EXPANDED;

export function getSpecialtyMarketDemandExpanded(
  key: SpecialtyMarketDemandExpandedKey,
): ServiceLandingExpandedContent {
  return SPECIALTY_EXPANDED[key];
}
